CAPITAL COMMITMENT |
6 Months Ended | 12 Months Ended |
|---|---|---|
Mar. 31, 2025 |
Sep. 30, 2024 |
|
| Maius Pharmaceutical Co. Ltd [Member] | ||
| Restructuring Cost and Reserve [Line Items] | ||
| CAPITAL COMMITMENT | (14) Capital Commitment
Consultant fees
On September 13, 2022, the Company and Elite Rainbow Limited (“Elite”) entered a “Listing Advisory Agreement” with major terms as follows: (ⅰ) Elite serves as the sole advisor for the Company to list on the U.S stock market; (ⅱ) Elite will pay IPO related expenses for the Company who would return the expenses when it sucessfully lists on stock market or refinances. (iii) The Company has to issue Ordinary Shares for US$30,741 to Elite, based on the net assets of US$435,500 of the Company as of September 30, 2022; (iv) The Company will pay US$3,000,000 to Elite as consulting fee if it successfully lists on U,S stock market, such fee is exempted if failure on listing.
|
(13) Capital Commitment
Consultant fees
On September 13, 2022, the Company and Elite Rainbow Limited (“Elite”) entered a “Listing Advisory Agreement” with major terms as follows: (ⅰ) Elite serves as the sole advisor for the Company to list on the U.S stock market; (ⅱ) Elite will pay IPO related expenses for the Company which would return the expenses when it successfully lists on a stock market or refinances. (iii) The Company issued Ordinary Shares for US$30,741 to Elite, based on the net assets of US$435,500 of the Company as of September 30, 2022; (iv) The Company will pay US$3,000,000 to Elite as consulting fee if it lists on U.S stock market, which fee is exempted if there is no listing.
|